While adverse events (AEs) were reported for 97% of trial participants, such cases were predominantly mild to moderate.

A new statistical models shed light on why some patients can extend the dosing interval with Eylea (aflibercept) from 8 weeks ...

Subgroup analyses of the PHOTON trial show visual acuity gains across subgroups by race, baseline visual acuity and retina ...

Regeneron Pharmaceutical (NASDAQ:REGN) fell 2% after a court rejected its request for a temporary injunction blocking sales ...

On September 23, 2024, Judge Kleeh of the Northern District of West Virginia denied Regeneron Pharmaceuticals, Inc.’s ...

Researchers assessed the efficacy of aflibercept 8 mg vs conventional 2 mg doses at 96 weeks in patients with diabetic ...

Regeneron Pharmaceuticals Inc. (REGN) announced positive three-year (156-week) data for EYLEA HD (aflibercept) Injection 8 mg from an ...

Regeneron spent $5 billion repurchasing shares from Sanofi in May 2020 and $900 million repurchasing global rights to Libtayo in July 2022, yet a windfall from sales of its Covid antibody cocktail as ...

The most pressing challenges include the financial and emotional burdens associated with frequent, long-term treatments for ...

Fintel reports that on October 16, 2024, Scotiabank initiated coverage of Ocular Therapeutix (NasdaqGM:OCUL) with a Sector ...

CHICAGO, CA, UNITED STATES, October 18, 2024 /EINPresswire / -- The Global Age-Related Macular Degeneration (AMD) <a target=_blank href= ...

The global Retinal Vein Occlusion (RVO) treatment market was valued at approximately USD 2.65 billion in 2023 and is projected to exhibit a compound annual growth rate (CAGR) of 6.92% over the ...